|Bid||109.32 x 800|
|Ask||109.35 x 1300|
|Day's Range||107.27 - 112.56|
|52 Week Range||63.41 - 140.36|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||74.11|
|Earnings Date||Aug. 04, 2020 - Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||141.57|
Today we are going to look at Haemonetics Corporation (NYSE:HAE) to see whether it might be an attractive investment...
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.
Haemonetics (HAE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
To the annoyance of some shareholders, Haemonetics (NYSE:HAE) shares are down a considerable 31% in the last month...
Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll show...
Haemonetics (HAE) delivered earnings and revenue surprises of 23.68% and 2.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / February 4, 2020 / Haemonetics Corp. (NYSE:HAE) will be discussing their earnings results in their 2020 Third Quarter Earnings to be held on February 4, 2020 at 8:00 AM Eastern ...
While Haemonetics Corporation (NYSE:HAE) shareholders are probably generally happy, the stock hasn't had particularly...